First-Line Treatment for Acquired von Willebrand Syndrome

This protocol covers the first-line haemostatic management of Acquired von Willebrand syndrome. The approach is structured, requires individualised decision-making, and relies on close laboratory and clinical monitoring throughout.

Treatment Approach

Management centres on replacement with a plasma-derived concentrate containing von Willebrand factor. Dosing is not fixed — it is determined by the patient's individual profile and adjusted throughout treatment based on ongoing monitoring of vWF activity and clinical response. The complete structured regimen, including all dosing parameters, monitoring schedule, and decision algorithm, is in the full protocol.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.5603/ahp.107038

In our practice, we use initial doses of 30 to 100 units of vWF: RCo/kg, depending on the patient's residual activity, the severity of bleeding, and the presence of inhibitors.

Careful monitoring of clinical response and measurements of vWF concentrations is necessary to adjust doses and dosing intervals.

View source ↗